


Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care.

**Note:** Any pregnant patient presenting to MD Anderson should have a Maternal Fetal Medicine (MFM) consult prior to initiation of any treatment.

## INITIAL EVALUATION



### Special considerations:

- There should be open communication with the patient, obstetrician, and medical, surgical and radiation oncologists
- Surveillance of children exposed in utero to chemotherapeutic agents should be documented
- Surgery will not be performed at MD Anderson post 22 weeks gestation


<sup>1</sup> If metastatic disease at diagnosis, individualize treatment with multidisciplinary planning

<sup>2</sup> Patients with DCIS should not receive chemotherapy

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care.

**Note:** Any pregnant patient presenting to MD Anderson should have a Maternal Fetal Medicine (MFM) consult prior to initiation of any treatment.

## CLINICAL STAGE



### Special Considerations:

- There should be open communication with the patient, obstetrician, and medical, surgical and radiation oncologists
- Surveillance of children exposed in utero to chemotherapeutic agents should be documented
- Surgery will not be performed at MD Anderson post 22 weeks gestation


<sup>1</sup> Anthracycline therapy prior to taxane therapy is the preference

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care.

**Note:** Any pregnant patient presenting to MD Anderson should have a Maternal Fetal Medicine (MFM) consult prior to initiation of any treatment.

## CLINICAL STAGES

Clinical Stage II or III  
 or suspicion of distant  
 metastatic disease



### Special Considerations:

- There should be open communication with the patient, obstetrician, and medical, surgical and radiation oncologists
- Surveillance of children exposed in utero to chemotherapeutic agents should be documented
- Surgery will not be performed at MD Anderson post 22 weeks gestation

<sup>1</sup> Anthracycline therapy prior to taxane therapy is the preference

<sup>2</sup> Following the delivery of baby:

- Additional chemotherapy, endocrine, biologic therapy **and/or** radiation as clinically indicated
- Review labor, delivery, and neonatal records

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care.

## SUGGESTED READINGS

- Amant, F., Halaska, M. J., Fumagalli, M., Steffensen, K. D., Lok, C., Van Calsteren, K., ... Maxwell, C. (2014). Gynecologic cancers in pregnancy: Guidelines of a second international consensus meeting. *International Journal of Gynecological Cancer*, 24(3), 394-403. doi: 10.1097/IGC.0000000000000062
- Amant, F., von Minckwitz, G., Han, S. N., Bontenbal, M., Ring, A. E., Giermek, J., ... Neven, P. (2013). Prognosis of women with primary breast cancer diagnosed during pregnancy: Results from an international collaborative study. *Journal of Clinical Oncology*, 31(20), 2532-2539. doi:10.1200/JCO.2012.45.6335
- Azim, H. A., Santoro, L., Russell-Edu, W., Pentheroudakis, G., Pavlidis, N., & Peccatori, F. A. (2012). Prognosis of pregnancy-associated breast cancer: A meta-analysis of 30 studies. *Cancer Treatment Reviews*, 38(7), 834-842. doi:10.1016/j.ctrv.2012.06.004
- Beadle, B. M., Woodward, W. A., Middleton, L. P., Tereffe, W., Strom, E. A., Litton, J. K., ... Perkins, G. H. (2009). The impact of pregnancy on breast cancer outcomes in women  $\leq 35$  years. *Cancer*, 115(6), 1174-1184. doi:10.1002/cncr.24165
- Berry, D. L., Theriault, R. L., Holmes, F. A., Parisi, V. M., Booser, D. J., Singletary, S. E., ... Hortobagyi, G. N. (1999). Management of breast cancer during pregnancy using a standardized protocol. *Obstetrical & Gynecological Survey*, 54(10), 620-621. doi:10.1200/JCO.1999.17.3.855
- Fanale, M. A., Uyei, A. R., Theriault, R. L., Adam, K., & Thompson, R. A. (2005). Treatment of metastatic breast cancer with trastuzumab and vinorelbine during pregnancy. *Clinical Breast Cancer*, 6(4), 354-356. doi:10.3816/CBC.2005.n.040
- Hahn, K. M., Johnson, P. H., Gordon, N., Kuerer, H., Middleton, L., Ramirez, M., ... Theriault, R. L. (2006). Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. *Cancer*, 107(6), 1219-1226. doi:10.1002/cncr.22081
- Kuerer, H. M., Gwyn, K., Ames, F. C., & Theriault, R. L. (2002). Conservative surgery and chemotherapy for breast carcinoma during pregnancy. *Surgery*, 131(1), 108-110. doi:10.1067/msy.2002.115357
- Keleher, A. J., Theriault, R. L., Gwyn, K. M., Hunt, K. K., Stelling, C. B., Singletary, S. E., ... Kuerer, H. M. (2002). Multidisciplinary management of breast cancer concurrent with pregnancy. *Journal of the American College of Surgeons*, 194(1), 54-64. doi:10.1016/S1072-7515(01)01105-X
- Litton, J. K., Warneke, C. L., Hahn, K. M., Palla, S. L., Kuerer, H. M., Perkins, G. H., ... Theriault, R. L. (2013). Case control study of women treated with chemotherapy for breast cancer during pregnancy as compared with nonpregnant patients with breast cancer. *The Oncologist*, 18(4), 369-376. doi:10.1634/theoncologist.2012-0340
- Middleton, L. P., Amin, M., Gwyn, K., Theriault, R., & Sahin, A. (2003). Breast carcinoma in pregnant women. *Cancer*, 98(5), 1055-1060. doi:10.1002/cncr.11614
- Mir, O., Berveiller, P., Goffinet, F., Treluyer, J., Serreau, R., Goldwasser, F., & Rouzier, R. (2010). Taxanes for breast cancer during pregnancy: A systematic review. *Annals of Oncology*, 21(2), 425-426. doi:10.1093/annonc/mdp517
- Murthy, R. K., Theriault, R. L., Barnett, C. M., Hodge, S., Ramirez, M. M., Milbourne, A., ... Litton, J. K. (2014). Outcomes of children exposed in utero to chemotherapy for breast cancer. *Breast Cancer Research*, 16(6), 500. doi:10.1186/s13058-014-0500-0
- Theriault R., & Hahn K. (2007). Management of Breast Cancer in Pregnancy. *Current Oncology Reports*, 9(1), 17-21. doi:10.1007/BF02951421
- Yang, W. T., Dryden, M. J., Gwyn, K., Whitman, G. J., & Theriault, R. (2006). Imaging of Breast Cancer Diagnosed and Treated with Chemotherapy during Pregnancy 1. *Radiology*, 239(1), 52-60. doi:10.1148/radiol.2391050083

### Invited Articles

- Litton, J. K., & Theriault, R. L. (2010). Breast cancer and pregnancy: Current concepts in diagnosis and treatment. *The Oncologist*, 15(12), 1238-1247. doi:10.1634/theoncologist.2010-0262
- Theriault, R. L., & Litton, J. K. (2013). Pregnancy during or after breast cancer diagnosis: What do we know and what do we need to know? *Journal of Clinical Oncology*, 31(20), 2521-2522. doi:10.1200/JCO.2013.49.7347

Disclaimer: *This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care.*

---

## DEVELOPMENT CREDITS

This practice algorithm is based on majority expert opinion of the Breast Center Faculty at the University of Texas MD Anderson Cancer Center. It was developed using a multidisciplinary approach that included input from the following:

Olga N. Fleckenstein<sup>♦</sup>  
Henry Mark Kuerer, MD (Breast Surgical Oncology)  
Jennifer Litton, MD (Breast Medical Oncology)  
Andrea Milbourne, MD (Gynecologic Oncology & Reproductive Medicine)  
Tanya Moseley, MD (Diagnostic Radiology - Breast Imaging)  
Amy Pai, PharmD<sup>♦</sup>  
Vicente Valero, MD (Breast Medical Oncology)

<sup>♦</sup> Clinical Effectiveness Development Team